Novartis' Late Bloomer Entresto Leads Take-Off Of Heart Failure Market
Market snapshot: Growth of Novartis' Entresto along with greater use of SGLT-2 inhibitors and the entry of new branded drugs will boost sales of drugs for chronic heart failure from $4.6bn in 2017 to $10.1bn in 2026, despite wide availability of generics, according to a new Datamonitor forecast.
You may also be interested in...
Detailed data for omecamtiv mecarbil at AHA show a slim overall benefit, but Cytokinetics highlighted its effects in sicker patients and investigators emphasized the drug’s impact on reduced hospitalizations.
Patients with heart failure on Entresto say they have fewer symptoms and greater quality of life, according to a registry study and Novartis is hoping that this and other real world data will propel the drug towards its peak sales target of $5bn.
Novartis beat third-quarter forecasts, flagged its strengthening drug portfolio, and said its CEO transition remains on track for February 2018, but a decision on its eye care division awaits.